 |
|
 |
Oramed Pharmaceuticals (OTC:ORMP.OB) is developing proprietary technology for the oral delivery of drugs presently administered by way of injection. Through its patented flagship product, an oral insulin capsule currently in Phase 2 trials, the Company is seeking to revolutionize the treatment of diabetes. 
|
Press Release
June 10, 2009 Oramed Presents Poster at ADA in New Orleans
June 8, 2009 Open- Label Study to Assess the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Oral Insulin Formulation in Subjects with type 2 Diabetes (T2DM) ... read more » |
| Press Center | Terms & Conditions | Privacy Statement | All rights reserved © 2009 Oramed |